Press Releases - Enanta Pharmaceuticals, Inc.
Apr 30, 2024 · Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) September 3, 2024. Enanta Pharmaceuticals to Participate in Investor Conferences in September. August 5, 2024.
Enanta Pharmaceuticals Announces Positive Topline Results for …
Sep 26, 2024 · Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo. Favorable Safety and Tolerability Observed. Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today.
Enanta Pharmaceuticals Announces Positive Topline Results for …
Sep 26, 2024 · Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo. Favorable...
Enanta Pharmaceuticals, Inc. (ENTA) Stock Price, News, Quote …
Find the latest Enanta Pharmaceuticals, Inc. (ENTA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Enanta Pharmaceuticals Reports Positive Topline Results from …
May 8, 2023 · Study Met Primary Endpoints of Safety and Tolerability. Dose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to Placebo, Achieving Statistical Significance as Early as One Day After First Dose. No Difference in Viral Load Reduction; Rapid Decline Observed in All Study Arms.
Enanta Pharmaceuticals to Provide Updates on its Research and ...
Jan 4, 2024 · ENTA. Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for...
Enanta Pharmaceuticals Announces Positive Topline Results for …
Sep 26, 2024 · Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV).
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical …
Oct 17, 2022 · WATERTOWN, Mass.-- ( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver...
Enanta Pharmaceuticals, Inc. (ENTA) Latest Stock News - Seeking Alpha
Get the latest news and real-time alerts from Enanta Pharmaceuticals, Inc. (ENTA) stock at Seeking Alpha.
Home - Enanta Pharmaceuticals
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) Read More »
- Some results have been removed